Market Overview

Intercept Pharmaceuticals Tumbles On Safety Concern Allegations

Related ICPT
Intercept Presents New Data Analyses on Non-Invasive Liver Testing From FLINT Trial of Obeticholic Acid in Nonalcoholic Steatohepatitis at AASLD 2015
Intercept Presents New Primary Biliary Cholangitis Data at AASLD 2015
The Vetr community has downgraded $ICPT to 4-Stars (Vetr)

Intercept Pharmaceuticals (NASDAQ: ICPT) shares were trading in the red Tuesday morning.

The stock traded down to $215, a 17.3 percent drop after Adam Feuerstein of The Street said government scientists are concerned about the safety of the drug. However, the stock began a recovery shortly thereafter.

The company’s stock is up more than 280 percent this year, despite pulling back from $497 to $260 during April’s pharmaceutical meltdown. The company’s jump in price is the result of strong early results from the company’s liver disease study.

Despite the early positive results, according to The Street, the drug causes lipid abnormalities. Furthermore, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has asked the company to stop trials of the drug. NIDDK indicates that the trial trials are being stopped because efficacy has been reached along with the negative health effects.

Worse, the company was contacted about the lipid abnormalities at the beginning of the year, but chose not to disclose the information, claiming the company is uncertain of the statistical significance.

Shares of Intercept Pharmaceuticals traded down 5.12 percent to $246.70 during the premarket session and after market open, shares traded down over seven percent to $241.66.

Posted-In: Adam FeuersteinNews Rumors Pre-Market Outlook


Related Articles (ICPT)

View Comments and Join the Discussion!

Get Benzinga's Newsletters